 |
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2010, vol. 16, book 3
Subject Collection: Medicine
Page: 70 - 73
DOI: 10.5272/jimab.1632010_70
Online date: March 18, 2011
J of IMAB 2010; 16(3):70-73
OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
Deyan Davidov,
Department of Chemotherapy, Oncological Center, Medical University, Pleven, Bulgaria
ABSTRACT:
Objectives: Single agent intravenous Topotecan is an effective treatment for small cell lung cancer /SCLC/ after failure of first- line chemotherapy. The aim of this study was to evaluate the efficacy and toxicity of intravenous Topotecan in recurrent SCCC. Methods: In the period 2008- 2009 seventeen consecutive patients with relapsed SCLC entered the study. The treatment schedule consists of Topotecan 1,5 mg/m2 i.v. for five consecutive days, with repetition every 21 days. Results: Overall response rate was 23,5%. Median survival was 6,4 months. Nausea, vomiting and neutropenia were most common side effects. Conclusion: Intravenous Topotecan is effective as second- line therapy for patients with relapsed SCCC with good tolerability.
Key words: Relapsed small cell lung cancer, Second- line treatment, Intravenous Topotecan, Survival.
Page: 70-73; FULL TEXT PDF (108 KB) Abstract & References
Please include this information when citing this paper: DOI: 10.5272/jimab.1632010_70